Dr. Alexander Schueller to speak at Rejuvenation Startup Summit 2022
We are happy to announce Dr. Alexander Schueller, CEO of CellVie, as a speaker for the Rejuvenation Startup Summit 2022. Also meet Scientific Co-Founders Prof. Dr. James McCully, who invented the approach of Therapeutic Mitochondria Transplantation (TMT) and Dr. Sitaram Emani, having been the first to employ TMT clinically at Boston Children’s Hospital.
Cellvie is a Harvard spin-off pioneering Therapeutic Mitochondria Transfer (TMT) leveraging the therapeutic potential of mitochondria.
The company was founded by Drs. McCully, Schueller, del Nido and Emani. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury and beyond to slow or reverse degenerative processes of aging linked to the mitochondria.
Dr. Alex Schueller is a repeat-entrepreneur in the life sciences, having co-founded, built and successfully exited Adhesys Medical, after starting his professional career at The Boston Consulting Group. Alex had known Pedro from his first venture and when he was introduced to therapeutic mitochondria transplantation (TMT), he was immediately captivated by the opportunity to bring about a novel category of cell-derived medicines. Alex is particularly keen to develop TMT as a platform, to realize its full potential.
Alex is CEO of cellvie Inc.
Prof. Dr. James McCully (Jim) is a world-leading expert in mitochondria biology and cardioprotection. He invented the approach of Therapeutic Mitochondria Transplantation (TMT) at Harvard Medical School as a means to ameliorate ischemia-reperfusion injury. Jim was inspired by his observation that mitochondria dysfunction arose during ischemia, but none of the treatment approaches seemed to have a profound impact on reversing the functional deterioration. He developed his hypothesis of transplanting healthy, viable mitochondria for cell-rescue. He has since expanded on these observations to demonstrate safety and efficacy of mitochondrial transplantation for ischemia-reperfusion injury along with methodologies for mitochondria preparation and delivery.
Jim is Co-Founder of cellvie Inc.
Dr. Sitaram Emani (Ram) is a highly accomplished cardiothoracic pediatric surgeon, focusing on complex repairs at Boston Children’s Hospital. He has a strong track-record in translating novel therapies into clinical practice, particularly in the cell- and gene therapy space. When Ram became aware of therapeutic mitochondria transplantation (TMT) through his work with Jim and Pedro, he was immediately attracted by the approach’s potential to aide myocardial recovery after a cardiogenic shock. He is the Principle Investigator in the ongoing clinical trial at Boston Children’s Hospital, having been the first to employ TMT clinically.
Ram is Co-Founder of cellvie Inc.
About the Rejuvenation Startup Summit 2022
The Rejuvenation Startup Summit (Berlin, Oct. 14-15, 2022) hosted by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry.
Rejuvenation/Longevity biotech is a new, emerging field of medicine. It aims to prevent and reverse diseases of aging by addressing their common root cause, the aging process itself. Rejuvenation therapies aim to reverse or repair age-related cellular changes such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production.
The Rejuvenation Summit brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in founding or joining a startup – all aiming to create therapies to vastly extend the healthy human lifespan.
Further information can be found at www.forever-healthy.org/summit/
Founded in the US and headquartered close to Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond.
Further information can be found at www.cellvie.bio.
For free media & press passes, please contact:
Frank Schueler, COO Forever Healthy Foundation